Impact of Asthma Severity and Exacerbation Frequency on Burden of Disease Related Costs in Finland
A substantial disease burden associated with frequent exacerbations in both patients with asthma and severe asthma leads to increased productivity loss and direct healthcare costs. The estimated the total annual cost of working-aged patients with asthma was €715 million in Finland, with 25% of additional costs associated with frequent exacerbations, indicating the potential savings that could be achievable through improved disease control.
Authors
- Arja Viinanen (ORCID: https://orcid.org/0000-0003-4990-6228)
- Juhani Aakko (ORCID: https://orcid.org/0000-0003-4142-3256)
- Sara Hallberg (ORCID: https://orcid.org/0000-0003-2164-8060)
- Hannu Kankaanranta (ORCID: https://orcid.org/0000-0001-5258-0906)
- Paula Kauppi (ORCID: https://orcid.org/0000-0002-1065-330X)
- Mariann I. Lassenius (ORCID: https://orcid.org/0000-0003-0511-3939)
- Mary Dillon (ORCID: https://orcid.org/0000-0003-2072-296X)
- Kaisa Nieminen
- Lauri Lehtimäki (ORCID: https://orcid.org/0000-0003-1586-4998)
Institutions
- University of Helsinki (FI)
- University of Turku (FI)
- Tampere University (FI)
- Seinäjoki University of Applied Sciences (FI)
- Helsinki University Hospital (FI)
- Turku University Hospital (FI)
- Tampere University Hospital (FI)
- Tampere University (FI)
- AstraZeneca (Finland) (FI)
- Nordic School of Public Health (SE)
- University of Gothenburg (SE)
Publication Details
- Journal
- Journal of Asthma and Allergy
- Published
- 2025-10-01
- DOI
- https://doi.org/10.2147/jaa.s546092
- Citations
- 1
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- AstraZeneca